TABLE II.
Correlation analyses according to the characteristics of the selected studies
| Variable | Observations (n) | Spearman correlation coefficient | p Value |
|---|---|---|---|
| Median age | |||
| ≤65 Years | 20 | 0.753 | ≤0.001 |
| >65 Years | 7 | 0.964 | ≤0.001 |
| Median follow-up | |||
| ≤30 Months | 9 | 0.917 | 0.001 |
| >30 Months | 9 | 0.619 | NS |
| Chemotherapy | 12 | 0.781 | 0.003 |
| Immunotherapy | 7 | 0.786 | 0.036 |
| Combination chemotherapy | 3 | −0.500 | NS |
| Combination chemoimmunotherapy | 4 | 1.000 | NS |
| Line of treatment | |||
| First | 10 | 0.388 | NS |
| Second and subsequent | 17 | 0.589 | 0.013 |
| Median prior treatments | |||
| ≤2 | 17 | 0.664 | 0.004 |
| >2 | 8 | 0.738 | 0.037 |
| Median β2-microglobulin > 3.5 mg/L | 8 | 0.643 | NS |
| ≥50% of population with | |||
| Unmutated IgHV | 7 | 0.857 | 0.014 |
| ECOG PS | |||
| 0 | 5 | −0.667 | NS |
| 1 | 6 | 0.771 | NS |
| 0–1 | 4 | 0.800 | NS |
| Binet stage | |||
| B | 6 | 0.543 | NS |
| C | 3 | 1.000 | NS |
| Rai classification | |||
| IV | 5 | 0.900 | 0.037 |
| I–II | 7 | 0.536 | NS |
| III–IV | 5 | −0.100 | NS |
| Riska | |||
| Intermediate | 9 | 0.441 | NS |
| High | 13 | 0.465 | NS |
| Intermediate or high | 22 | 0.797 | ≤0.001 |
| Median time, diagnosis to study entry | |||
| ≤30 Months | 4 | 0.400 | NS |
| >30 Months | 7 | 0.536 | NS |
a
Based on Binet stage and Rai classification. Rai class 0 or Binet stage A, or both, corresponds with low-risk disease; Rai class I–II or Binet stage B, or both, corresponds with intermediate-risk disease; Rai class III–IV or Binet stage C, or both, corresponds with high-risk disease.
NS = statistically nonsignificant; ECOG PS = Eastern Cooperative Oncology Group performance status.